Status: Recruiting
Adenovirus (RGDCRAdCOX2F)
This is a single center, Phase I dose finding study of a single direct tumor injection of an RGD modified conditionally replicative adenovirus (RGDCRAdcox2F) in persons with adenocarcinoma of the pancreas. The study is designed to determine the MTD of RGDCRAdCOX2F that corresponds to the maximum desired toxicity of ≤ 20%.
Participants needed: 18
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Masonic Cancer Center, University of MinnesotaUpdated: Jan 7, 2026Locations: 1
Eligibility criteria
Histologically documented pancreatic adenocarcinoma that is confined to the panc... [+5]
Pregnant or breastfeeding. Persons of child-bearing potential must have a negati... [+11]